Skip to main content

rivaroxaban (Xarelto®)


Status: In progress

Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment.

 Draft Recommendation: rivaroxaban (Xarelto) 3875 (PDF, 169Kb)

Medicine details

Medicine name rivaroxaban (Xarelto®)
Formulation 1 mg/1ml granules for oral suspension; 15 mg and 20 mg film-coated tablet
Reference number 3875

As above

Company Bayer Healthcare Pharmaceuticals
BNF chapter Cardiovascular system
Submission type Licence extension for paediatric use
Status In progress
AWMSG meeting date 08/12/2021
Date of issue TBC